Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “fruquintinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 10
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 10 pipeline programs matching "fruquintinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

10 results for “fruquintinib” Back to intelligence hub

Search results

  1. Cetuximab β;Fruquintinib;

    Zhejiang University

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial
  2. Fruquintinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Fruquintinib

    phase 2 small molecule active

    1 trial
  3. Fruquintinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 2 small molecule active

    1 trial
  4. Fruquintinib

    RenJi Hospital

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial
  5. Fruquintinib

    Dai, Guanghai

    Colorectal Cancer Metastatic

    phase 2 small molecule active

    1 trial
  6. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial
  7. XELOX combined with Fruquintinib and Sintilimab

    The First People's Hospital of Lianyungang

    Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial
  8. fruquintinib

    Takeda

    Colon Cancer

    phase 2 small molecule active

    1 trial
  9. Fruquintinib

    Takeda

    Colorectal Cancer

    approved small molecule active

    1 trial
  10. Fruquintinib and Everolimus

    The First People's Hospital of Lianyungang

    Renal Cell Carcinoma, Clear Cell, Somatic

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.